Table 1.

Selected clinical trials for CARTs in haematological malignancies

Study	Phase	Condition or disease included in data analysis	CART generation	Costimulatory domain	Target molecule	Outcome (n/n infused)	References
NCT01593696	I	ALL	2nd	CD28	CD19	CR: 70% (14/20)	Lee et al. (2015)
NCT01044069	I	ALL	2nd	CD28	CD19	CR: 83% (44/53)	Park et al. (2018)
NCT02028455 (PLAT-02)	I/II	ALL	2nd	4-1BB	CD19	CR: 93% (40/43)	Gardner et al. (2017)
NCT02772198	I/II	ALL	2nd	CD28	CD19	CR: 90% (18/20)	Jacoby et al. (2018)
NCT02435849 (ELIANA)	II	ALL	2nd	4-1BB	CD19	CR: 81% (61/75); FDA approval for ALL	Maude et al. (2018)
NCT01029366	I	CLL	2nd	4-1BB	CD19	OR: 57% (8/14; 4 CR and 4 PR)	Porter et al. (2015)
NCT01416974	I	CLL	2nd	CD28	CD19	OR: 38% (3/8; 2 CR and 1 PR)	Geyer et al. (2018)
NCT01865617	I/II	CLL	2nd	4-1BB	CD19	OR: 74% (14/19; 4 CR and 10 PR)	Turtle et al. (2017)
NCT03331198 (TRANSCEND CLL 004)	I/II	CLL	2nd	4-1BB	CD19	OR: 87% (13/15; 7 CR and 8 PR)	Siddiqi et al. (2019)
NCT00924326	I	DLBCL	2nd	CD28	CD19	OR: 68% (13/19; 9 CR and 4 PR)	Kochenderfer et al. (2017)
NCT02631044 (TRANSCEND NHL 001)	I	DLBCL	2nd	4-1BB	CD19	OR: 68% (89/131; 64 CR and 25 PR)	Abramson et al. (2020)
NCT02348216 (ZUMA-1)	I/II	DLBCL, PMBCL, tFL	2nd	CD28	CD19	OR: 83% (84/101; 59 CR and 25 PR); FDA approval for DLBCL	Viardot et al. (2019)
NCT02445248 (JULIET)	II	DLBCL	2nd	4-1BB	CD19	OR: 52% (48/93; 37 CR and 11 PR); FDA approval for DLBCL	Schuster et al. (2018)
NCT02215967	I	MM	2nd	CD28	BCMA	OR: 81% (13/16; 2 sCR, 8 VGPR and 3 PR)	Brudno et al. 2018
NCT02658929	I	MM	2nd	4-1BB	BCMA	OR: 85% (28/33; 15 CR and 13 PR)	Raje et al. (2019)
NCT01886976	I/II	MM	2nd	4-1BB	CD138	OR: 80% (4/5; 3 SD	Guo et al. (2016)

ALL acute lymphoblastic leukemia, CLL chronic lymphocytic leukemia, DLBCL diffuse large B-cell lymphoma, PMBCL primary mediastinal B-cell lymphoma, tFL transformed follicular lymphoma, MM multiple myeloma, OR overall response, CR complete response, sCR stringent complete response, PR partial response, VGPR very good partial response, SD stable disease